AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial.

The deal includes a $350 million upfront payment to the company, Gubra, for the rights to its drug, called for now GUB014295. AbbVie will pay up to some $1.9 billion if certain development and sales milestones are met.

The agreement comes less than a year since Robert Michael took over as CEO of AbbVie and as the company looks for its next top-selling drugs following the loss of patent protection for its mega blockbuster autoimmune treatment Humira. In a statement, Michael said that the Gubra partnership offers “a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance – Biotech Investments

Evolva Holding SA / Key word(s): Strategic Company Decision 14-Jun-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

June 15, 2023

England’s MMR vaccinations up 23% following NHS initiative – Pharmaceutical Technology

Share this article Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent

April 5, 2024

Is the worst over? Catalent touts GLP-1 and gene therapy business as it sticks to financial guidance

Catalent’s financial health appears to be on the mend thanks to specific segments of its manufacturing business, but the CDMO still has a long road

November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.